Iovance Biotherapeutics (Mfg)
Philadelphia, PA
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
70.8
Signal Score
○ FDA Inspections
✓ Clinical Trials (31)
✓ SEC Filings (13)
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Iovance Biotherapeutics (Mfg)
- Signal Score
- 70.8/100 (as of 2026-09-07)
- Quality Compliance
- Assessment pending
- Headquarters
- Philadelphia, PA
- Modalities
- Cell Therapy
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Iovance Biotherapeutics (Mfg)
CDMO.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Operations
74.5
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
NCT07288203
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in...
PHASE2
Active Not Recruiting
NCT06940739
A Study to Investigate the Safety and Efficacy of IOV-3001 in...
PHASE1/PHASE2
Recruiting
View all 31 programs →
Source: ClinicalTrials.gov · Retrieved Oct 06, 2026
Financial Stability
71.0
13 SEC filings with industry mentions on record
SEC Filings13 with industry mentions
Capacity
66.0
Profile-based capacity assessment
Clinical Activity 31 studies
NCT07700121
PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma
EARLY_PHASE1
Not Yet Recruiting
NCT07741877
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With...
PHASE2
Not Yet Recruiting
NCT07192900
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
PHASE1
Recruiting
NCT07288073
TIL Therapy in cSCC and MCC
PHASE2
Recruiting
NCT07288203
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With...
PHASE2
Active Not Recruiting
NCT05639972
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally...
PHASE1/PHASE2
Recruiting
NCT06940739
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With...
PHASE1/PHASE2
Recruiting
NCT06481592
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With...
PHASE2
Recruiting
NCT06151847
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion...
PHASE2
Completed
NCT05727904
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With...
PHASE3
Recruiting
NCT05686226
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
PHASE2
Recruiting
NCT05607095
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma,...
PHASE1
Recruiting
NCT05483491
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
PHASE1
Recruiting
NCT05361174
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in...
PHASE1/PHASE2
Recruiting
NCT05176470
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for...
PHASE1
Active Not Recruiting
NCT04614103
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
PHASE2
Recruiting
NCT04155710
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of...
PHASE1
Completed
NCT04111510
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated...
PHASE2
Completed
NCT04052334
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent...
PHASE1
Completed
NCT03935347
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in...
PHASE2
Withdrawn
+ 11 more studies
Source: ClinicalTrials.gov · Retrieved Oct 06, 2026
Financial Intelligence
"
Iovance was founded to build upon the promise of TIL cell therapy initially developed at academic research centers, including the National Cancer Institute, or the NCI."
"Our multi-center trials, scalable manufacturing, regulatory approvals and commercial infrastructure have transformed TIL cell therapy from a research product available to only a small number of patients, into a commercially viable treatment that is accessible for thousands of cancer patients."
"
Amtagvi
®
is the first one-time, individualized T cell therapy for a solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanoma."
"launch of Amtagvi
®
(lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi
®
treatment regimen and in other applications."
"Amtagvi
®
is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
"launch of Amtagvi
®
(lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi
®
treatment regimen and in other applications."
"Amtagvi
®
is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
"launch of Amtagvi
®
(lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi
®
treatment regimen and in other applications."
"Amtagvi
®
is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
"launch of Amtagvi
®
(lifileucel), the first product within our autologous TIL cell therapy platform, while also marketing Proleukin
®
(aldesleukin), an interleukin-2, or IL-2, product used in the Amtagvi
®
treatment regimen and in other applications."
"Amtagvi
®
is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid tumor cancer."
"Iovance was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute, or the NCI."
"launch of Amtagvi™ (lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi™ treatment regimen."
"Amtagvi™ is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
"launch of Amtagvi™ (lifileucel), the first product within its autologous TIL cell therapy platform, and Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi™ treatment regimen."
"Amtagvi™ is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
"launch of Amtagvi™ (lifileucel), the first product within its autologous TIL cell therapy platform, and Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi™ treatment regimen."
"Amtagvi™ is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid tumor cancer."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic centers, including the National Cancer Institute (“NCI”)."
Source: SEC EDGAR · Retrieved Oct 06, 2026
Frequently Asked Questions About Iovance Biotherapeutics (Mfg)
How many clinical programs is Iovance Biotherapeutics (Mfg) linked to?
Iovance Biotherapeutics (Mfg) is associated with 31 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Iovance Biotherapeutics (Mfg)'s CDMO Signal Score?
Iovance Biotherapeutics (Mfg) has a Signal Score of 71/100, based on quality, operations, financial stability, and capacity data.
Evaluating Iovance Biotherapeutics (Mfg) for a manufacturing program?
Use the free AI matchmaker to compare Iovance Biotherapeutics (Mfg) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.3
CAR-T, Cell Therapy
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Signal Score: 74.5
mRNA, Gene Therapy, Cell Therapy, Lentiviral
Minaris (WuXi Advanced Therapies)
Philadelphia, PA / Yokohama, Japan
Signal Score: 60.5
CAR-T, Cell Therapy
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 91.1
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC